Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in refractory non-infectious uveitis
ChiCTR2100048030Phase 2Recruiting
- Sponsor
- Tongji Hospital
- Start
- Jul 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of baricitinib in uveitis, Hyalitis, posterior uveitis and 2 more, sponsored by Tongji Hospital. Primary endpoint: Vision at 20 weeks. Started Jul 2021; status: recruiting.
02
Drugs
baricitinib
03
Conditions
uveitisHyalitisposterior uveitispanuveitisVogt-Koyanagi-Harada disease (VKH)
Beyond the preview
Go deeper on ChiCTR2100048030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048030.